Advertisement

Topics

Luminex Company Profile

12:00 EST 18th December 2018 | BioPortfolio

Luminex Corporation was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life-sciences industry. The company’s open-architecture xMAP® technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately.Systems using xMAP technology (formerly known as LabMAP®) perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.

Location

12212 Technology Blvd
Austin
Texas
78727
United States of America

Contact

Phone: 512.219.8020 or 888.219.8020
Fax: 512.219.5195
Email: info@luminexcorp.com


News Articles [20 Associated News Articles listed on BioPortfolio]

Merck verkauft Amnis® Flow Cytometry und Guava® Technologies an Luminex Corporation

- Alle zugehörigen Reagenzien dieser Marken werden von Luminex übernommen - Strategische Vereinbarung ermöglicht es Luminex, die Präsenz im Multi-Milliarden-Dollar-Markt für Durchflusszytometrie ...

Luminex kündigt Dividende für das dritte Quartal an

Das amerikanische Biotechnologieunternehmen Luminex Corporation (ISIN: US55027E1029, NASDAQ: LMNX) wird seinen Aktionären für das dritte Quartal eine Dividende von 0,06 US-Dollar je Aktie ausbezahl....

Luminex zahlt Dividende für das vierte Quartal

Das amerikanische Biotechnologieunternehmen Luminex Corporation (ISIN: US55027E1029, NASDAQ: LMNX) wird seinen Aktionären für das vierte Quartal eine Dividende von 0,06 US-Dollar je Aktie ausbezahl....

Merck KGaA verkauft Durchflusszytometrie-Geschäft an Luminex

FRANKFURT (Dow Jones)--Merck verkauft einen Bereich zur Analyse von Zellen und Submikronpartikeln in die USA. Das sogenannte Durchflusszytometrie-Geschäft werde an die Luminex Corporation für 62,5.....

Luminex starts clinical trials for VERIGENE II gastrointestinal assay

Luminex has started clinical studies for the gastrointestinal (GI) assay on the VERIGENE II system.

Luminex to acquire MilliporeSigma's flow cytometry portfolio for USD 75 million

Luminex Corporation announced that the company has signed a definitive agreement to acquire MilliporeSigma's flow cytometry portfolio for USD 75 million, consisting of approximately USD 69.9 million ...

Merck KGaA to sell Reagent Arm to Luminex

Merck KGaA, the German pharmaceuticals, chemicals and laboratory science group, is selling its MilliporeSigma Flow Cytometry unit to Luminex, based at Austin, Texas, in the US. The transaction worth &...

Merck sells its Flow Cytometry unit for €62.5 million

Merck announced the signing of a definitive agreement to sell its Flow Cytometry unit to Luminex Corporation for €62.5 million. The closing of the transaction, expected by the end of 2018, is subjec...

Drugs and Medications [0 Results]

None

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Comparison of two Luminex Single-Antigen bead flow cytometry assays for detection of Donor Specific Antibodies after renal transplantation.

Defining the clinical relevance of Donor Specific HLA antibodies (DSA) detection by Luminex Single Antigen (LSA) flow beads assay is critical in monitoring posttransplant outcome.

Establishment of xMAP for the simultaneous detection of antibodies to Newcastle disease virus and avian influenza virus.

Using Luminex xMAP (x = analyte, MAP = multi-analyte profiling) technology, a serological method for the simultaneous detection of antibodies to Newcastle disease virus (NDV) and avian influenza virus...

Development and evaluation of two multi-antigen serological assays for the diagnosis of bovine tuberculosis in cattle.

There is currently an increased interest in the use of serological approaches in combination with traditional cell-mediated immunity-based techniques to improve the detection of tuberculosis (TB)-infe...

Sensitive detection of live Escherichia coli by bacteriophage amplification-coupled immunoassay on the Luminex® MAGPIX instrument.

Phages are natural predators of bacteria and have been exploited in bacterial detection because of their exquisite specificity to their cognate bacterial hosts. In this study, we present a "proof of c...

Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation.

Formation of de novo donor-specific antibodies (dn-DSAs) has been associated with longterm immunologic complications after liver transplantation (LT). We hypothesized that human leukocyte antigen (HLA...

Clinical Trials [12 Associated Clinical Trials listed on BioPortfolio]

Cytokine Evaluation of Accelerated Tooth Movement

Gingival Crevicular Fluid samples will be collected using periopapers after accelerated tooth movement technique, results will be achieve with cytokine measurements that will be done using...

Fluency Stent-Graft Versus Luminex Stent for Angioplasty of Recurrent Stenosis of the Cephalic Arch in Autogenous Arteriovenous (AV) Access for Hemodialysis

The type of hemodialysis access and preservation of this access greatly influences the quality of life and survival of patients undergoing hemodialysis. The Kidney Disease Outcomes Quality...

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

This is a phase i randomized, double blind clinical trial designed to evaluate the safety, tolerability and immunogenicity of the ID93 recombinant protein antigen alone or formulated with ...

ZRx-101 (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia

The ZRx-101 cells have features similar to activated NK cells, but mediate superior anti-tumor activity against hematologic and solid tumor targets in vitro and in vivo. The utilization of...

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects

This is a China registration study. A randomized, double-blind, placebo-controlled immunogenicity and safety study in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to...

Companies [5 Associated Companies listed on BioPortfolio]

Luminex

Luminex Corporation was incorporated in May 1995 and began commercial production of our first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biologic...

Luminex Corp.

Luminex Corporation

One Lambda Inc.

One Lambda Inc. is a world leader in the manufacture of HLA medical diagnostic products based in Canoga Park, California. The company is committed to develop products that improve...

AllerGenis

Established in 2017 and located in Hatfield, PA, AllerGenis develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess an...

More Information about "Luminex" on BioPortfolio

We have published hundreds of Luminex news stories on BioPortfolio along with dozens of Luminex Clinical Trials and PubMed Articles about Luminex for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Luminex Companies in our database. You can also find out about relevant Luminex Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Corporate Database Quicklinks



Searches Linking to this Company Record